GLP-1
The Ozempic Price War: How a 71% Medicare Discount is Reshaping Healthcare Finance
A landmark 71% Medicare price cut on Ozempic and Wegovy signals a major shift in healthcare finance, impacting investors, the economy, and Big Pharma.
The Hundred-Billion-Dollar Pill: Inside Pfizer’s High-Stakes Gamble to Conquer the Weight-Loss Market
Pfizer is betting billions on an oral weight-loss pill to challenge Novo Nordisk and Eli Lilly’s injectable dominance in a market poised to hit $100B.
Pfizer’s $10 Billion Gambit: Winning the War for Metsera and the Future of Weight Loss
Pfizer outmaneuvered rival Novo Nordisk in a $10bn bidding war for weight-loss startup Metsera, a strategic move to combat its looming patent cliff.
Pharma’s High-Stakes Gamble: Inside the Pfizer vs. Novo Bidding War for a Weight-Loss Unicorn
A fierce bidding war erupts between Pfizer and Novo Nordisk for biotech firm Metsera, signaling a high-stakes battle for the future of the obesity drug market.
Pfizer’s $100 Billion Gamble: Inside the High-Stakes Battle for the Weight-Loss Drug Crown
Pfizer is playing hardball in the $100B weight-loss drug market, betting its future on a pill to challenge the injectable giants, Novo Nordisk and Eli Lilly.
The Rybelsus Revelation: Why One Chart Correction Unlocks Novo Nordisk’s True Value
A minor chart correction for Novo Nordisk reveals a major lesson in financial analysis, highlighting the crucial difference between its diabetes and obesity drugs.
The Ozempic Economy: How a Weight-Loss Shot is Reshaping Markets and Killing the Business Lunch
A new class of weight-loss drugs is shaking up the economy, impacting the stock market and threatening the future of the traditional business lunch.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.